Immunomodulatory therapy, risk factors and outcomes of hospital-acquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case–control matched multicentre study (BACTCOVID)

OBJECTIVES: The effect of the use of immunomodulatory drugs on the risk of developing hospital-acquired bloodstream infection (BSI) in patients with COVID-19 has not been specifically assessed. We aim to identify risk factors for, and outcomes of, BSI among hospitalized patients with severe COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Abelenda-Alonso, Gabriela, Rombauts, Alexander, Gudiol, Carlota, Oriol, Isabel, Simonetti, Antonella, Coloma, Ana, Rodríguez-Molinero, Alejandro, Izquierdo, Elisenda, Díaz-Brito, Vicens, Sanmartí, Montserrat, Padullés, Ariadna, Grau, Inmaculada, Ras, Mar, Bergas, Alba, Guillem, Lluïsa, Blanco-Arévalo, Alejandro, Alvarez-Pouso, Claudia, Pallarés, Natalia, Videla, Sebastián, Tebé, Cristian, Carratalà, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260492/
https://www.ncbi.nlm.nih.gov/pubmed/34242804
http://dx.doi.org/10.1016/j.cmi.2021.06.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260492/
https://www.ncbi.nlm.nih.gov/pubmed/34242804
http://dx.doi.org/10.1016/j.cmi.2021.06.041

Ejemplares similares